Xencor, Inc. (NASDAQ:XNCR), reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. On Thursday shares of Xencor, Inc. (NASDAQ:XNCR) closed at $15.53.
IPO for Flex Pharm (NASDAQ: FLKS) opened for trading at $19 after pricing 5,400,000 shares of common stock at a public offering price of $16 per share. Flex Pharma, Inc. (NASDAQ:FLKS) in last trading activity moved down -6.56% to close at $14.95.
Minerva Neurosciences, Inc. (NASDAQ:NERV) on 21st January announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. On last trading day Minerva Neurosciences, Inc. (NASDAQ:NERV) moved down -6.52% to close at $4.59. Its volatility for the week is 6.77% while volatility for the month is 11.67%. Minerva Neurosciences, Inc. (NASDAQ:NERV) monthly performance is -17.00%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported a fourth-quarter net loss to company of $176.66 million or $0.74 per share, compared to profit of $44.29 million or $0.19 per share, prior year. Adjusted loss per share was $0.55, for the quarter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has 0.50% insider ownership while its institutional ownership stands at 98.40%. In last trading activity company’s stock closed at $114.14.
Canaccord Genuity reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research note issued to investors on Tuesday. The firm currently has a $30.00 price target on the stock. On last trading day Xenon Pharmaceuticals Inc. (NASDAQ:XENE) moved down -5.53% to close at $17.24. Its volatility for the week is 7.43% while volatility for the month is 9.19%. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) monthly performance is -13.41%.